Evidence map›Paper›PMID 26659582›Full record

Trial reportPloS one2015

Prediction of Long-Term Benefits of Inhaled Steroids by Phenotypic Markers in Moderate-to-Severe COPD: A Randomized Controlled Trial.

Jiska B Snoeck-Stroband, Therese S Lapperre, Peter J Sterk, Pieter S Hiemstra, Henk A Thiadens, H Marike Boezen, Nick H T Ten Hacken, Huib A M Kerstjens, Dirkje S Postma, Wim Timens and 2 more

Registry-linked trialOpen access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00158847 (Modification of Disease Outcome in COPD. Shortterm Versus Longterm Treatment With Inhaled Corticosteroids, Either or Not Combined With a Long-Acting Beta2-Agonist.), which is not on this map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00158847 phase4terminatednot on this map

Modification of Disease Outcome in COPD. Shortterm Versus Longterm Treatment With Inhaled Corticosteroids, Either or Not Combined With a Long-Acting Beta2-Agonist.

TypeinterventionalSponsorLeiden University Medical CenterRan2000 to 2005Enrolled200ConditionsChronic Obstructive Pulmonary DiseaseArmsfluticasone 500 mcg, fluticasone 500 mcg + salmeterol 50 mcg
3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Pharmacotherapy of chronic obstructive pulmonary disease: Therapeutic considerations with a focus on inhaled corticosteroids.South African family practice : official journal of the South African Academy of Family Practice/Primary Care · 2020
    Article
  5. Inhaled Corticosteroids in COPD: Trying to Make a Long Story Short.International journal of chronic obstructive pulmonary disease · 2020
    Review
  6. Article
  7. Article
  8. Inhaled corticosteroids in COPD: Personalising the therapeutic choice.African journal of thoracic and critical care medicine · 2018
    Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Jiska B Snoeck-StrobandDepartment of Public Health and Primary Care, Leiden University Medical Center, Leiden, The Netherlands.
Therese S LapperreDepartment of Pulmonology, Leiden University Medical Center, Leiden, The Netherlands.
Peter J SterkDepartment of Pulmonology, Leiden University Medical Center, Leiden, The Netherlands.
Pieter S HiemstraDepartment of Pulmonology, Leiden University Medical Center, Leiden, The Netherlands.
Henk A ThiadensDepartment of Public Health and Primary Care, Leiden University Medical Center, Leiden, The Netherlands.
H Marike BoezenUniversity of Groningen, University Medical Center Groningen, Department of Epidemiology, Groningen, The Netherlands.
Nick H T Ten HackenUniversity of Groningen, University Medical Center Groningen, Department of Pulmonology, Groningen, The Netherlands.
Huib A M KerstjensUniversity of Groningen, University Medical Center Groningen, Department of Pulmonology, Groningen, The Netherlands.
Dirkje S PostmaUniversity of Groningen, University Medical Center Groningen, Department of Pulmonology, Groningen, The Netherlands.
Wim TimensUniversity of Groningen, University Medical Center Groningen, Department of Pathology, Groningen, The Netherlands.
Jacob K SontDepartment of Medical Decision Making, Leiden University Medical Center, Leiden, The Netherlands.
GLUCOLD Study Group
Leiden University Medical Center · NLUniversity of Groningen · NLUniversity Medical Center Groningen · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe decline in lung function can be reduced by long-term inhaled corticosteroid (ICS) treatment in subsets of patients with chronic obstructive pulmonary disease (COPD). We aimed to identify which clinical, physiological and non-invasive inflammatory characteristics predict the benefits of ICS on lung function decline in COPD.

methodsAnalysis was performed in 50 steroid-naive compliant patients with moderate to severe COPD (postbronchodilator forced expiratory volume in one second (FEV1), 30-80% of predicted, compatible with GOLD stages II-III), age 45-75 years, >10 packyears smoking and without asthma. Patients were treated with fluticasone propionate (500 μg bid) or placebo for 2.5 years. Postbronchodilator FEV1, dyspnea and health status were measured every 3 months; lung volumes, airway hyperresponsiveness (PC20), and induced sputum at 0, 6 and 30 months. A linear mixed effect model was used for analysis of this hypothesis generating study.

resultsSignificant predictors of attenuated FEV1-decline by fluticasone treatment compared to placebo were: fewer packyears smoking, preserved diffusion capacity, limited hyperinflation and lower inflammatory cell counts in induced sputum (p<0.04).

conclusionsLong-term benefits of ICS on lung function decline in patients with moderate-to-severe COPD are most pronounced in patients with fewer packyears, and less severe emphysema and inflammation. These data generate novel hypotheses on phenotype-driven therapy in COPD.

trial registrationClinicalTrials.gov NCT00158847.

Indexed as

Administration, InhalationAdrenal Cortex HormonesAgedBronchodilator AgentsDrug Administration ScheduleFemaleFluticasoneForced Expiratory VolumeHumansLungMaleMiddle AgedPhenotypePlacebo EffectPulmonary Disease, Chronic ObstructiveSeverity of Illness IndexAdrenal Cortex HormonesBronchodilator AgentsFluticasone

Identifiers

PMID26659582
PMCPMC4699453
OpenAlexW2195026601

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.